Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions

肺癌并发肺纤维化:2004年至2024年文献计量分析——研究现状、趋势及未来方向

阅读:1

Abstract

OBJECTIVE: Although research on the association between pulmonary fibrosis and lung cancer is of great significance, to date, no bibliometric analysis has been conducted on the comorbidity of these two diseases. This study aims to explore the current status and cutting - edge trends in this field through bibliometric analysis, and to establish new directions for future research. METHODS: Using the Web of Science Core Collection database, statistical calculations, graphic, and data visualization tools such as CiteSpace, VOSviewer, and Biblimatrix - biblioshiny were adopted. RESULTS: A total of 2,234 original Articles and Reviews on pulmonary fibrosis complicated by lung cancer published between 2004 and 2024 were identified. A slow growth trend in publications related to pulmonary fibrosis complicated by lung cancer was observed. The United States, Japan, and China were the countries with the greatest contributions. Professor Michael Kreuter from Marienhaus Clinic, Mainz, Germany, and the University of Michigan published the most articles. Through cluster analysis of co - cited literature, five main clusters were identified. Keyword analysis predicted that "nintedanib", "pirfenidone", "immunotherapy", etc. might become hot topics in the field of the comorbidity of pulmonary fibrosis and lung cancer. CONCLUSION: This bibliometric analysis shows that the literature related to the comorbidity of pulmonary fibrosis and lung cancer is on a continuous upward trend. The research hotspots and trends identified in this study provide a reference for in - depth research in this field, aiming to promote the development of research on the comorbidity of pulmonary fibrosis and lung cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。